



## **Cohere Medicare Advantage Policy – Gastric Pacing/Electrical Stimulation**

*Clinical Policy for Medical Necessity Review*

**Version: 1.1**

**Cohere Health UMC Approval Date: February 6, 2025**

Last Annual Review: Not Applicable

Revision: November 18, 2025

Next Annual Review: February 6, 2026

# Important Notices

## Notices & Disclaimers:

**GUIDELINES ARE SOLELY FOR COHERE’S USE IN PERFORMING MEDICAL NECESSITY REVIEWS AND ARE NOT INTENDED TO INFORM OR ALTER CLINICAL DECISION-MAKING OF END USERS.**

Cohere Health, Inc. (“**Cohere**”) has published these clinical guidelines to determine the medical necessity of services (the “**Guidelines**”) for informational purposes only, and solely for use by Cohere’s authorized “**End Users**”. These Guidelines (and any attachments or linked third-party content) are not intended to be a substitute for medical advice, diagnosis, or treatment directed by an appropriately licensed healthcare professional. These Guidelines are not in any way intended to support clinical decision-making of any kind; their sole purpose and intended use is to summarize certain criteria Cohere may use when reviewing the medical necessity of any service requests submitted to Cohere by End Users. Always seek the advice of a qualified healthcare professional regarding any medical questions, treatment decisions, or other clinical guidance. The Guidelines, including any attachments or linked content, are subject to change at any time without notice. This policy may be superseded by existing and applicable Centers for Medicare & Medicaid Services (CMS) statutes.

© 2025 Cohere Health, Inc. All Rights Reserved.

---

## Other Notices:

HCPCS® and CPT® copyright 2025 American Medical Association. All rights reserved.

Fee schedules, relative value units, conversion factors and/or related components are not assigned by the AMA, are not part of CPT, and the AMA is not recommending their use. The AMA does not directly or indirectly practice medicine or dispense medical services. The AMA assumes no liability for data contained or not contained herein.

HCPCS and CPT are registered trademarks of the American Medical Association.

---

## Policy Information:

**Specialty Area:** Gastroenterology/Urology/Disorders of the Musculoskeletal System

**Policy Name:** Gastric Pacing/Electrical Stimulation

**Type:**  Adult (18+ yo) |  Pediatric (0-17 yo)

## **Table of Contents**

<b>Important Notices</b>	<b>2</b>
<b>Medical Necessity Criteria</b>	<b>4</b>
<b>Service: Gastric Pacing/Electrical Stimulation</b>	<b>4</b>
Related CMS Documents	4
Description	4
Medical Necessity Criteria	5
Indications	5
Non-Indications	5
Definitions	5
Level of Care Criteria	5
Procedure Codes (CPT/HCPCS)	5
Evaluation of Clinical Harms and Benefits	7
<b>Medical Evidence</b>	<b>9</b>
<b>References</b>	<b>10</b>
<b>Policy Revision History/Information</b>	<b>11</b>

# Medical Necessity Criteria

## **Service: Gastric Pacing/Electrical Stimulation**

### **Related CMS Documents**

Please refer to the [CMS Medicare Coverage Database](#) for the most current applicable CMS National Coverage.<sup>1-4</sup>

- [National Coverage Determination \(NCD\). Electrical nerve stimulators \(160.7\)](#)
- [National Coverage Determination \(NCD\). Sacral nerve stimulation for urinary incontinence \(230.18\)](#)
- [Local Coverage Determination \(LCD\). Sacral nerve stimulation for the treatment of urinary and fecal incontinence \(L39543\)](#)
- [Local Coverage Determination \(LCD\). Peripheral nerve stimulation \(L34328\)](#)

### **Description**

Electrical stimulation is a treatment modality that modulates the inappropriate or excessive activity of nerves through the surgical implantation of a device that generates an electrical pulse to stimulate the nerves of a specific region. Several types of neurostimulators exist.

- Gastric electrical stimulation (GES) is an advanced treatment for gastroparesis, a condition that manifests as delayed movement of food from the stomach to the small intestine. This may result in chronic nausea, vomiting, abdominal pain, bloating, and nutritional deficiency. Although gastroparesis may be well-controlled through less invasive methods, including dietary modification and medical therapy, a small percentage of patients experience refractory gastroparesis that causes intractable nausea and vomiting. Among such patients, gastric electrical stimulation is indicated, wherein a neurostimulator device is surgically placed beneath the skin to direct electrical impulses to the smooth muscle of the stomach. For appropriately selected patients, this often confers an improvement in symptoms and an overall improved quality of life.<sup>5-6</sup>
- More than one-fifth of adults in the United States suffer from chronic pain.<sup>7</sup> Peripheral nerve stimulation is approved by the US Food & Drug

Administration for the treatment of chronic pain affecting the lower back, extremities, trunk, head, and face. A neurostimulator device is implanted in the appropriate area, and electrodes are placed near the affected peripheral nerves (i.e., nerves located outside of the brain and spinal cord). It is reserved for patients who have not attained adequate pain control through conventional treatment.

- Fecal incontinence and urinary complications are the primary indications for sacral neurostimulation. The neurostimulator device is positioned to deliver electrical impulses to the sacral nerves, which control bowel and bladder function. It is an advanced tool for patients who have failed conventional, conservative therapy. Patient outcomes and quality of life are improved among appropriately selected patients.<sup>5-6, 8-9</sup>

## Medical Necessity Criteria

### Indications

**Electrical neurostimulation** is considered appropriate if **ANY** of the following is **TRUE**:

- **Gastric electrical stimulation (GES)** is considered appropriate if **ALL** of the following are **TRUE**:
  - Documented confirmation of gastroparesis (gastric emptying delay with >10% tracer retention at 4 hours) on a 4-hour scintigraphic gastric emptying test<sup>5,8</sup>; **AND**
  - Predominant symptom is nausea or vomiting;<sup>5,8</sup> **AND**
  - Other anatomic/organic cause for symptoms has been excluded with upper endoscopy and selective imaging, if clinically indicated<sup>5,8</sup>; **AND**
  - Failure of **ALL** of the following:
    - Dietary modification (adoption of a small particle diet)<sup>5,8</sup>; **AND**
    - Over-the-counter (OTC) therapy<sup>5,8</sup>; **AND**
    - Anti-emetics<sup>5,8</sup>; **AND**
    - Prokinetics<sup>5,8</sup>; **OR**
- **Peripheral nerve stimulation** is considered appropriate if **ALL** of the following are **TRUE**:
  - Chronic, severe pain for at least 3 months; **AND**
  - Failure of less invasive treatment modalities and medications<sup>1,4</sup>; **AND**

- Appropriate surgical candidate (no infection or relevant medical risks)<sup>1,4</sup>; **AND**
- Appropriate proper patient education, discussion and disclosure of risks and benefits<sup>1,4</sup>; **AND**
- No active substance abuse<sup>1,4</sup>; **AND**
- Formal psychological screening by a mental health professional<sup>1,4</sup>; **AND**
- Successful stimulation trial with greater than or equal to 50% reduction in pain intensity or 50% reduction in analgesic use before permanent implantation<sup>1,4</sup>; **OR**
- **Sacral nerve stimulation** is considered appropriate if **ALL** of the following are **TRUE**:
  - **ANY** of the following:
    - Urinary urge incontinence<sup>2-3</sup>; **OR**
    - Urinary frequency syndrome<sup>2-3</sup>; **OR**
    - Urinary retention<sup>2-3</sup>; **OR**
    - Chronic fecal incontinence with greater than 2 incontinent episodes on average per week for a duration of more than 6 months<sup>3</sup>; **AND**
  - Failure or intolerance of conventional therapy (behavioral, pharmacologic, dietary, or surgical corrective therapy)<sup>2-3</sup>; **AND**
  - Appropriate surgical candidate (no infection or relevant medical risks)<sup>2-3</sup>; **AND**
  - Ability to record voiding diary data such that clinical results of the implant procedure may be properly evaluated<sup>2-3</sup>; **AND**
  - Successful stimulation trial with greater than or equal to 50% sustained (more than 48 hours) reduction in symptoms<sup>2-3</sup>; **OR**
- **Removal, revision, or replacement** of an existing neurostimulation device that is nonfunctioning, has a depleted battery, or is damaged (fractured leads or other damage).<sup>1-6</sup>

## Non-Indications

**Electrical neurostimulation** is not considered appropriate if **ANY** of the following is **TRUE**:

- **Gastric pacing/gastric neurostimulation** is not considered appropriate if **ANY** of the following is **TRUE**:
  - Current opioid use<sup>5,8</sup>; **OR**
  - Cannabinoid hyperemesis<sup>5,8</sup>; **OR**
  - Predominant symptom of gastroparesis is abdominal pain, bloating, or discomfort<sup>5,8</sup>; **OR**
  - Cyclic vomiting syndrome in absence of other criteria<sup>5,8</sup>; **OR**
  - Diabetes mellitus in absence of other criteria<sup>5,8</sup>; **OR**
  - Obesity in absence of other criteria<sup>5,8</sup>; **OR**
  - Eating disorder in absence of other criteria<sup>5,8</sup>; **OR**
  - Psychogenic vomiting in absence of other criteria<sup>5,8</sup>; **OR**
  - Functional dyspepsia in absence of other criteria<sup>5,8</sup>; **OR**
  - Congenital hypertrophic pyloric stenosis in absence of other criteria<sup>5,8</sup>; **OR**
- **Peripheral neurostimulation** is not considered appropriate if **ANY** of the following is **TRUE**:
  - Fibromyalgia<sup>1,4</sup>; **OR**
  - Phantom limb pain<sup>1,4</sup>; **OR**
  - Diffuse polyneuropathy<sup>1,4</sup>; **OR**
  - Nociceptive pain in trunk or lower back<sup>1,4</sup>; **OR**
  - Angina pectoris<sup>1,4</sup>; **OR**
- **Sacral neurostimulation** is not considered appropriate if **ANY** of the following is **TRUE**:
  - Stress incontinence<sup>2,3</sup>; **OR**
  - Urethral obstruction or stricture<sup>2,3</sup>; **OR**
  - Diabetes with peripheral nerve involvement<sup>2,3</sup>; **OR**
  - Multiple sclerosis<sup>2,3</sup>; **OR**
  - Benign prostatic hypertrophy<sup>2,3</sup>; **OR**
  - Chronic constipation<sup>2,3</sup>; **OR**
  - Fecal incontinence that is related to rectal intussusception<sup>1,4,15</sup>; **OR**
  - Chronic pelvic pain in the absence of other criteria<sup>2,3</sup>; **OR**
  - Fecal incontinence that is related to anorectal malformation<sup>2,3</sup>; **OR**
  - Fecal incontinence that is related to peripheral neuropathy or complete spinal cord injury.<sup>2,3</sup>

## Level of Care Criteria

Outpatient

### Procedure Codes (CPT/HCPCS)

CPT/HCPCS Code	Code Description
64590	Insertion or replacement of peripheral, sacral, or gastric neurostimulator pulse generator or receiver, requiring pocket creation and connection between electrode array and pulse generator or receiver
64595	Revision or removal of gastric neurostimulator pulse generator
43647	Laparoscopy, surgical; implantation or replacement of gastric neurostimulator electrodes, antrum
43648	Laparoscopy, surgical; revision or removal of gastric neurostimulator electrodes, antrum
43881	Implantation or replacement of gastric neurostimulator electrodes, antrum, open
43882	Revision or removal of gastric neurostimulator electrodes, antrum, open

**Disclaimer:** S Codes are non-covered per CMS guidelines due to their experimental or investigational nature.

## **Evaluation of Clinical Harms and Benefits**

Clinical determinations for Medicare Advantage beneficiaries are made in accordance with 42 CFR 422.101 guidance outlining CMS's required approach to decision hierarchy in the setting of NCDs/LCDs identified as being "not fully established". When clinical coverage criteria are "not fully established" Medicare Advantage organizations are instructed to create publicly accessible clinical coverage criteria based on widely-accepted clinical guidelines and/or scientific studies backed by a robust clinical evidence base. Clinical coverage criteria provided by Cohere Health in this manner include coverage rationale and risk/benefit analysis.

**The potential clinical harms** of using these criteria may include:

- Device-associated risks are possible with the implantation of nerve stimulators. These complications include infection, pain at the stimulation site, erosion of the device through the skin or stomach wall, excessive bleeding, and inadequate treatment of symptoms.
- Risks with inappropriate surgical procedures include infection, bleeding, injury to neurovascular structures, lead migration, anesthetic risk, and the need for repeat or additional procedures. If a patient has an inappropriate surgical procedure, this can lead to additional complications, necessitating further invasive management; therefore, careful patient selection is in the patient's best interest.
- Increased healthcare costs and complications from the inappropriate use of emergency services and additional treatments.

**The potential clinical benefits** of using these criteria include:

- Nerve stimulators may offer symptom relief for patients who have exhausted other treatment options, including patients with intractable vomiting or recurrent incontinence. Non-opioid treatment of chronic pain may be possible with peripheral nerve stimulators.
- As compared to traditional treatment, including major procedures such as urostomy/colostomy formation for chronic incontinence, nerve stimulators are relatively less invasive and less expensive. Minimally invasive procedures confer a better patient safety profile and tend to require a shorter recovery period and a minimal (or eliminated) hospital stay.
- Enhanced overall patient satisfaction and healthcare experience.

## Medical Evidence

Electrical nerve stimulation has been used to modulate pain, incontinence, vomiting, and other debilitating symptoms since the 1960s. At present, a range of devices exist to therapeutically stimulate the gastric, peripheral, and sacral nerves.

The American College of Gastroenterology (ACG) and the American Gastroenterological Association (AGA) have published guidance around the use of electrical stimulation for gastroparesis. The ACG endorses the treatment of medically refractory gastroparesis with gastric electrical stimulation. Importantly, this is a conditional recommendation made with low-quality evidence.<sup>5</sup> The AGA's 2022 clinical practice guidelines encouraged clinicians to consider electrical stimulation only for those patients with intractable and refractory nausea and vomiting, provided that they had no success with conventional therapy and were not taking opioids. These professional guidelines underscore the importance of appropriate patient selection.<sup>7</sup> Gastric pacing remains an advanced therapy for patients who have exhausted other treatment options. A 2024 systemic review and meta-analysis by Saleem et al. examined a total of 730 patients with gastric stimulators. At one year following implantation, patients saw a significantly improved gastrointestinal total symptom score (TSS), reduced frequency in vomiting episodes, improved gastric emptying study, and improved quality of life. The authors concluded that gastric electrical stimulation remains a treatment option for gastroparesis that is refractory to traditional treatment, acknowledging gastroparesis as a high-burden disease with an associated elevated mortality rate.<sup>10</sup>

In 2024, the American Society of Interventional Pain Physicians (ASIPP) published evidence-based recommendations to guide the use of implanted peripheral nerve stimulators to manage chronic pain. Based on fair-quality evidence, they issued a recommendation of moderate strength for the use of peripheral stimulators in patients with chronic pain that is moderate or severe in nature, has failed two or more conventional treatments, and has successfully responded to a trial period with a test stimulation device. The authors note that the evidence base remains low-quality and heterogeneous,

positing that this has impeded the field’s ability to reach a definitive consensus regarding appropriate use. In 2022, the American Society of Pain and Neuroscience (ASPN) published similar guidelines reviewing specific scenarios for peripheral nerve stimulation. All discussed scenarios received a recommendation of level B or C (“recommendable” or “neither recommendable nor inadvisable”).<sup>11-12</sup>

Sacral nerve stimulation provides bladder and bowel control when it is absent or impaired. The American Society of Colon and Rectal Surgeons (ASCRS) issued practice guidelines in 2023 to aid in the treatment of fecal incontinence. Sacral neuromodulation was felt to be a conditional recommendation, and the authors noted the relative dearth of knowledge around sacral nerve stimulation as compared to other techniques. In their review of the literature, sacral nerve stimulation offers at least a 50% improvement in symptoms for many patients. Sacral neuromodulation may confer greater efficacy than optimal medical therapy for certain patients. The American Urological Association (AUA) has also published guidance for the use of electrical stimulation among patients with urinary dysfunction. A variety of common urological problems, including overactive bladder and urge incontinence, are improved with sacral nerve stimulation when patients have failed traditional therapy. An exception to this is urinary retention, which does not require failure of conservative therapy if sacral nerve stimulation is considered as an alternative to intermittent self-catheterization.<sup>6,9</sup>

## References

1. Centers for Medicare & Medicaid Services (CMS). National Coverage Determination (NCD). Electrical nerve stimulators (160.7). Effective date August 7, 1995.  
<https://www.cms.gov/medicare-coverage-database/view/ncd.aspx?NCID=240>
2. Centers for Medicare & Medicaid Services (CMS). National Coverage Determination (NCD). Sacral nerve stimulation for urinary incontinence (230.18). Effective date January 1, 2002.  
<https://www.cms.gov/medicare-coverage-database/view/ncd.aspx?ncdid=249&ncdver=1&bc=0>
3. Centers for Medicare & Medicaid Services (CMS). Local Coverage Determination (LCD). Sacral nerve stimulation for the treatment of urinary and fecal incontinence (L39543). Effective Date November 5, 2023.  
<https://www.cms.gov/medicare-coverage-database/view/lcd.aspx?lcdid=39543&ver=5&bc=0>
4. Centers for Medicare & Medicaid Services (CMS). Local Coverage Determination (LCD). Peripheral nerve stimulation (L34328). Revision Effective Date December 1, 2019.  
<https://www.cms.gov/medicare-coverage-database/view/lcd.aspx?lcdid=39543&ver=5&bc=0>
5. Camilleri M, Kuo B, Nguyen L, et al. ACG clinical guideline: gastroparesis. *Official journal of the American College of Gastroenterology*. ACG. 2022 Aug 1;117(8):1197-220.
6. Ginsberg DA, Boone TB, Cameron AP, et al. The AUA/SUFU guideline on adult neurogenic lower urinary tract dysfunction: treatment and follow-up. *Journal of Urology*. 2021 Nov 1;206(5):1106-13.
7. Rikard SM, Strahan AE, Schmit KM, et al.. Chronic pain among adults – United States, 2019–2021. *MMWR Morb Mortal Wkly Rep* 2023;72:379–385. DOI: <http://dx.doi.org/10.15585/mmwr.mm7215a1>.

8. Lacy BE, Tack J, Gyawali CP. AGA clinical practice update on management of medically refractory gastroparesis: expert review. *Clinical Gastroenterology and Hepatology*. 2022 Mar 1;20(3):491-500.
9. Bordeianou LG, Thorsen AJ, Keller DS, et al. The American Society of Colon and Rectal Surgeons clinical practice guidelines for the management of fecal incontinence. *Diseases of the Colon & Rectum*. 2023 May 1;66(5):647-61.
10. Saleem S, Aziz M, Khan AA, et al. Gastric electrical stimulation for the treatment of gastroparesis or gastroparesis-like symptoms: A systemic review and meta-analysis. *Neuromodulation: Technology at the Neural Interface*. 2024 Feb 1;27(2):221-8.
11. Strand N, D'Souza RS, Hagedorn JM, et al. Evidence-based clinical guidelines from the American Society of Pain and Neuroscience for the use of implantable peripheral nerve stimulation in the treatment of chronic pain. *Journal of Pain Research*. 2022 Jan 1:2483-504.
12. Manchikanti L, Sanapati MR, Soin A, et al. Comprehensive evidence-based guidelines for implantable peripheral nerve stimulation (PNS) in the management of chronic pain: From the American Society Of Interventional Pain Physicians (ASIPP). *Pain Physician*. 2024;27(S9):S115-S191.
13. Katuwal B, Bhullar J. Current position of sacral neuromodulation in treatment of fecal incontinence. *Clinics in Colon and Rectal Surgery*. 2021 Jan;34(01):022-7.
14. Prapasrivorakul S, Gosselink M, Gorissen KJ, et al. Sacral neuromodulation for faecal incontinence: Is the outcome compromised in patients with high-grade internal rectal prolapse?. *International journal of colorectal disease*. 2015 Feb;30:229-34.

# Policy Revision History/Information

Original Date: February 6, 2025		
Review History		
Version 1.1	11/18/2025	<p>Policy re-formatted to reflect current template.</p> <p>Policy updated to reflect CMS updates:</p> <p>Link and reference for L34328 updated 10/23/2025 with no coverage changes by CMS.</p> <p>L37360 removed from policy - Retired by CMS 10/23/2025.</p> <p>Updated CMS-related references.</p>